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Teaser The Stanford SPARK program is an innovative academic–industry partnership for
translating academic biomedical research. This article highlights SPARKs model, which can
provide a template for other universities and institutions interested in de-risking and
facilitating the translation of biomedical research.
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Translating academic medical research into new therapies is an
important challenge for the biopharmaceutical industry and investment
communities, which have historically favored later-stage assets with
lower risk and clearer commercial value. The Stanford SPARK program
is an innovative model for addressing this challenge. The program was
created in 2006 to educate students and faculty about bringing academic
research from bench to bedside. Every year, the program provides
mentorship and funding for approximately a dozen SPARK ‘scholars,’
with a focus on impacting patient lives, regardless of economic factors.
By reviewing the detailed structure, function and operation of SPARK
we hope to provide a template for other universities and institutions
interested in de-risking and facilitating the translation of
biomedical research.
Introduction
In this case study we profile the structure and impact of the SPARK Translational Research
Program at Stanford University School of Medicine, a partnership between academics and
individual experts in industry dedicated to overcoming the hurdles of translating academic
discoveries into drugs and diagnostics that address unmet clinical needs. SPARK’s underlying
philosophy is that academia has an important part to play in decreasing the time and cost of
developing new therapeutics and diagnostics that benefit society. By studying this innovative
partnership, we aim to provide a template for other universities and academic medical centers
interested in launching their own translational medicine accelerators.
Academia — defined here to include nonprofit universities and scientific research institutions
— is a major stakeholder that can play an important part in progressing medical development.
The interactions between academia, the pharmaceutical industry and regulatory authorities are
of paramount importance for ensuring the quality, efficacy and safety of drugs in clinical andPlease cite this article in press as: D.O.C.Kim, D.O.C. Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine, Drug Discov
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partnerships among stakeholders and accelerate the commerciali-
zation of biomedical research.
Translational medicine background
The past few decades have brought tremendous breakthroughs in
the fundamental knowledge necessary for understanding, pre-
venting, diagnosing and treating many diseases—breakthroughs
such as human genome sequencing, immunotherapies and gene
therapies. However, the process of translating new discoveries into
products severely lags behind the pace of discovery. The transition
period when a developing technology is seen as promising but is
too new to validate its commercial potential and unable to attract
the necessary funding for its continued development has been
coined the ‘valley of death’ [1]. Investors are reluctant to bear the
full cost of entering the valley of death, owing to the high risk and
historically low return on investment for early-stage R&D. Conse-
quently, only 12% of active preclinical assets reside in large
pharmaceutical companies [2], and 80–90% of biomedical re-
search projects never progress to trials in humans [1].
Translational medicine is a growing field, focused on addres-
sing this gap between medical discovery and commercialization
[3]. Within the past decade, the National Institutes of Health
(NIH) has made translational research a priority, forming the
National Center for Advancing Translational Sciences (NCATS)
and launching the Clinical and Translational Science Award
(CTSA) program in 2006. Additionally, at least three journals
are devoted to furthering the field: Science Translational Medicine,
Journal of Translational Medicine and New Horizons in Translational
Medicine.
The risk-averse attitude in industry opposes the culture of
academia, where risk-taking is often rewarded by promotion
and recognition. The essential role of academic institutions in
commercial drug development calls for a better funding mecha-
nism to reward academic contributions and a more efficient
academic–industry collaboration. Although this process is com-
plicated by the fact that academic and commercial interests are not
always aligned, an evolving hybrid drug discovery model can be
useful in mitigating risks and increasing productivity. SPARK
provides one such example (Fig. 1).Please cite this article in press as: D.O.C.Kim, D.O.C. Accelerating biomedical innovation: a ca
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FIGURE 1
SPARK fills the gap between academic discovery and industry.
2 www.drugdiscoverytoday.comThe origin and mission of SPARK
The SPARK program was founded in 2006 by Professor Daria
Mochly-Rosen, who came up with the idea while serving as Senior
Associate Dean for Research in the Dean’s Office of Stanford
University School of Medicine. Two years before her appointment,
she had taken a leave of absence from Stanford to found her own
company, KAI Pharmaceuticals, which was subsequently acquired
by Amgen in 2011. From her experience with KAI, Dr Mochly-
Rosen found that bridging the translational research gap was
extremely challenging and not necessarily an intuitive process
for academics. Recognizing the need for education and funding to
help her academic colleagues translate their research into thera-
pies, Dr Mochly-Rosen created SPARK with crucial early backing
from the Dean’s Office of the School of Medicine, which allocated
the funds to launch the program and continues to provide finan-
cial support. Dr Mochly-Rosen then recruited Dr Kevin Grimes, an
academic internist with drug development experience, to join her
as co-director of the program. Now in its tenth year, SPARK offers
training, support and mentorship to academic researchers to
pursue basic research with potential medical applications. SPARK’s
stated goal is ‘to move five to ten new discoveries each year from
the lab to the clinic and/or to commercial drug and diagnostic
development’ [4].
How SPARK operates
The SPARK program is centered on its researchers. Selected project
leaders, called SPARK ‘scholars,’ receive US$50 000 annually for
two years, in addition to extensive educational mentoring from
SPARK advisors. Every year, SPARK selects a class of 10–15 scholars
that remain in the program for a two-year cycle. Since SPARK
started accepting open applications in its fourth year, over 400
projects have been submitted for consideration in the program.
The SPARK scholars are required to attend interactive weekly
Wednesday meetings that include lectures from industry experts
and project updates that occur on alternate weeks. Although
funding is limited to the selected scholars, every university mem-
ber is welcome to attend the Wednesday meetings and engage in
educational sessions. Currently, 100 individuals, including scho-
lars, Stanford community members and SPARK advisor network
members, attend regularly.se study of the SPARK program at Stanford University, School of Medicine, Drug Discov
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project milestones are met. Once a milestone is achieved, addi-
tional funds can be requested for the next stage of development.
Any unused funds revert back to the general pool of funds,
managed centrally by SPARK. Access to Stanford’s infrastructure,
facilities and resources helps to maximize use of the US$50 000.
One key to SPARK’s success is its ability to tap into the medical
school’s resources, providing academic researchers with access to
clinicians to better understand the clinical implications of their
research.
A key element of the SPARK training is teaching investigators
to think using a translational approach. The scholars learn to
identify the unmet clinical need of the patient and to understand
the problem in tandem with product development. In other
words, they are trained to ‘keep the end in mind’ throughout
the process. SPARK uses project management tools such as target
product profiles and project timelines to help teams plan and
identify key milestones, necessary endpoints and crucial decision
points.
Management
The SPARK program, currently led by Drs Mochly-Rosen and
Grimes, operates with a management team of five individuals that
oversees communications with project teams, runs its weekly
meetings, oversees SPARK funds and otherwise manages opera-
tions. Although the majority of the funds for SPARK comes from
the Dean’s Office, the program operates independently within
Stanford University and is managed solely by the SPARK team.
The advisors
One of the most important keys to SPARK’s success is the advisor
network, thanks to its strength, expertise and engagement. Advi-
sors volunteer their time to work with SPARK projects, attend the
weekly meetings and participate in evaluating potential projects.
They have no ownership or rights to any inventions or intellectual
property from the program. As of 2016, SPARK had over 100
advisors with significant entrepreneurial or industry expertise in
drug development, generally in a specific therapeutic area. On
occasion, advisors are organized into working groups, focused on
areas such as medicinal chemistry, biologics, financing and ven-
ture capital, business development and clinical trial design.
To alleviate concerns about the disclosure of scholars’ research
and assets at the Wednesday meetings, SPARK mandates confi-
dentiality agreements for all attendees and has worked to create a
culture of trust and sharing within the program. Advisors remain
engaged because of their interest in the core science behind the
projects and the opportunity to remain part of such a strong
network of industry experts. Mentoring is an opportunity for these
advisors to have an additional impact on drug development in a
low-risk environment and continue to use the expertise and skills
gained from their industry experience. Further, working with a
mission-driven program dedicated to translational medicine offers
an opportunity to help bring impactful products to market, which
might not have been the primary focus of the advisors’ former for-
profit industry employers. The advisors’ commitment to further-
ing scientific knowledge without financial compensation main-
tains the integrity of the process and the mission of the SPARK
program.Please cite this article in press as: D.O.C.Kim, D.O.C. Accelerating biomedical innovation: a ca
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The SPARK program is funded primarily through the Dean’s Office
within the School of Medicine, with additional support from
nonprofit organizations and the NIH. SPARK receives no revenue
from its projects. Since 2006, US$7.1 million has been spent,
covering staff salaries, scholars’ research expenses and other pro-
gram expenses. Additional funding for the program comes from
the Children’s Health Research Institute and goes toward research
projects with a pediatric focus. It is a key element of the program to
operate on funds that are not tied to commercial incentives. The
program has always turned down funds from for-profit companies
because of differences in incentives. Whereas for-profit companies
are often driven by profitability, SPARK is primarily focused on
addressing unmet medical needs. Accepting funding from for-
profit companies such as big pharma could dilute the mission
and create real or perceived conflicts of interest.
Project selection
A significant factor contributing to the SPARK program’s accom-
plishments is the rigorous project selection process, conducted by
a handpicked committee each autumn. The committee typically
consists of the SPARK management team, two-to-three Stanford
faculty members and a dozen SPARK advisors. The three primary
criteria for successful applications are that the project addresses an
unmet clinical need, uses a novel approach and has the potential
for the SPARK program to improve its licensing and/or clinical trial
prospects over the two-year cycle. Notably, commercial potential
is not a factor in the selection process (See Supplementary material
online for further details on the project selection process).
Program results and benefits
The SPARK program has a unique and rigorous success metric. A
project is deemed successful only if it enters a clinical trial, is
licensed or transferred to an existing biopharmaceutical company,
or leads to the founding of a new startup. In the 10 years since
SPARK was founded, 74 projects have graduated from the program.
Of these, 24 were licensed to startup companies, eight were
licensed to existing companies, four have been transferred to
industry without licenses and 31 are in clinical trials (ten without
licenses). Together, this amounts to a success rate of 62% (Fig. 2)
(See Supplementary material online for an analysis of the unsuc-
cessful or ‘‘failed” SPARK projects).
Additionally, although the SPARK project selection process
focuses on unmet medical needs, the SPARK program generates
significant follow-on grants and funding to support further re-
search for Stanford. Thus far, SPARK has generated nearly US$38.7
million in additional grant funding, 4.95-times the amount
provided by the Dean’s office over the same period (Fig. 3). Because
follow-on grants were generally received in the second year of
SPARK participation, this multiple was calculated using a discount
rate of 5% and a funding interval of two years.
Keys to success
The keys to SPARK’s success include the strength of its structure
and management, collaborative culture, focus on its mission and,
in particular, its network of advisors. The combination of Stanford-
affiliated researchers and industry advisors leads to a distinctive
and necessary diversity of interests and experiences. Other pro-se study of the SPARK program at Stanford University, School of Medicine, Drug Discov
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FIGURE 3
SPARK has generated significant follow-on grants from 2007 to 2015.
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tive, whereas programs that have a single or few advisors lose the
checks and balances provided by a larger network. SPARK advisors
receive no financial compensation; they remain involved with the
program because they see value in SPARK’s model and mission.
Challenges and future plans
Financing
One major challenge for SPARK is to procure sustainable funding
for the program. Currently, the program relies heavily on institu-
tional funds, mainly from the medical school’s Dean’s Office, as
well as grants from nonprofit and government agencies. The
program takes no equity stake in projects, and receives no royalties
from its projects’ revenues or license deals, because profiting from
the projects’ commercial success would not align with SPARK’s
core educational and social mission. As it currently stands, the
program needs US$2–2.5 million a year in funding. Ironically,
according to the Dean’s Office, many donors find this too small of
an investment. Going forward, ways that SPARK might finance
itself include a long-term endowment or an annual allocation in
Stanford’s budget.
To expand SPARK’s impact, the program’s founders would like
to support projects further into the development cycle. Some
projects need more funding to reach a value inflection point;
for example, an antibody therapeutic cannot move forward with-
out humanization of the antibody—an endeavor that costs much
more than the typical SPARK investment of US$50 000–100 000.
However, expanding the program will require significantly more
funding than the program currently deploys.
Institutional support
Another key consideration is that SPARK’s longevity relies on the
continued partnership and support from the Stanford University
School of Medicine. Programs such as SPARK need institutional
buy-in, especially in the alignment of the broader university with
their key values. For such a partnership to thrive, institutions
cannot expect substantial revenues or rewards—although univer-
sities do benefit from increased success in commercializing intel-Please cite this article in press as: D.O.C.Kim, D.O.C. Accelerating biomedical innovation: a ca
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4 www.drugdiscoverytoday.comlectual property. Institutions must recognize the significance of
the less tangible benefits, such as the creation of a strong institu-
tional memory and infrastructure. For example, Stanford Univer-
sity benefits from the successes and engagement of former scholars
who find industry positions with the help of SPARK and continue
to remain involved in SPARK.
Measuring success
Drug development and the translation of research is a lengthy
endeavor, hence the long-term impact of SPARK is still unclear.
Although SPARK’s current success metric matches the contempo-
rary landscape, in moving forward SPARK will need to pinpoint the
right metrics and implement the necessary processes to track the
direct impact of its projects. Similarly, SPARK would benefit by
measuring the impact of the indirect benefits of the program to the
university, such as increased education and job placement in
industry.se study of the SPARK program at Stanford University, School of Medicine, Drug Discov
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In the recent decade since its launch, the program has learned
many things about the challenges of drug development, some of
them unique to academia. Projects are generally successful when
physician-scientists can identify a strong medical need, and when
they are based on strong science. Furthermore, a clear or identifi-
able pathway to patients is crucial for development.
SPARK has made significant progress in bridging the valley of
death, but its scope is currently limited to Stanford. Although
some might argue that SPARK is uniquely positioned to succeed
given the strength of Stanford University’s resources and its Silicon
Valley location, the SPARK founders envision SPARK-like pro-
grams at universities across the USA and abroad playing a larger
role in systemically affecting early-stage translational efforts.
SPARK-like programs have already been started in the USA and
in 24 universities in eight countries abroad [5]. These replication
efforts rely on an institution’s ability to obtain backing from the
local academic and biopharma communities, to create a strong
advisor network, to collaborate with technology licensing offices
and to maintain a strong biomedical research program.
Concluding remarks
SPARK has achieved remarkable success in translating biomedical
discoveries thus far. However, for SPARK to be an attractive model
for other institutions, the program will need to further articulate
success metrics and collect data from past and current scholars to
inform future decisions. Similarly, an understanding of project
failures can provide valuable information for future projects.
Because many benefits from SPARK cannot be easily quantified,
such as educational and professional enrichment, one challenge
SPARK faces is meaningfully capturing the impact of the program,
including total grants received, prestige of the program, impact on
university recruiting and the future successes of graduated SPARK
scholars.
Finally, stakeholders across the board, including the Dean’s
Office of the Stanford University School of Medicine, agree that
SPARK has the potential to initiate a critical conversation among
numerous stakeholders about the need for systemic change in
translational medicine. Such a conversation would not only re-
duce the barriers to drug development and increase the efficiencyPlease cite this article in press as: D.O.C.Kim, D.O.C. Accelerating biomedical innovation: a ca
Today (2017), http://dx.doi.org/10.1016/j.drudis.2017.03.015of the entire biopharma industry but could get more life-saving
therapies into the hands of doctors and patients sooner.
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